Search for a trial | Research with human participants

1 results

A phase 4, monocenter, randomized, double-blind, placebo-controlled, 4-armed cross-over mechanistic intervention study to assess the renal hemodynamic effect of mono- and combination therapy with empagliflozin (SGLT-2 inhibitor) and losartan (RAS inhibitor) in metformin and/or SU-treated patients with type 2 diabetes mellitus

Approved WMORecruitment stopped

Investigate the effects of 7 (+-1) days of of mono- and combination therapy with the SGLT2 inhibitor empagliflozin (10 mg QD) and RAS inhibitor losartan (50 mg QD) on renal hemodynamics, (glomerular filtration rate (GFR) / effective renal plasma…